Recognized in Best Lawyers since 2020 
Dr. Jürgen Meier is a partner at Vossius & Partner Patentanwälte Rechtsanwälte mbB in Munich, where his practice focuses on Intellectual Property Law, particularly inbiotechnology and pharmaceutical technologies. He studied biology and biochemistry at the universities of Freiburg im Breisgau, Sussex (England), and Dundee (Scotland). Following the completion of his Ph.D. at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Dr. Meier conducted research for several years at the Centre de Recherche en Neuroscience at McGill University in Montréal, Canada. He joined VOSSIUS & PARTNER in 1998, qualified as a European Patent Attorney in 2001, and became a partner of the firm in 2004. Dr. Meier is also admitted to practice as a German Patent Attorney (Patentanwalt) and European Trademark Attorney.
Within his Intellectual Property Law practice, Dr. Meier handles patent prosecution, opposition and revocation proceedings, as well as matters related to patent infringement. His work frequently involves biotechnology and pharmaceutical innovations, including antibody technologies, therapeutic biologics, and small molecule pharmaceuticals. His experience includes matters involving antibody-based medicines such as blinatumomab, trastuzumab, and rituximab, as well as technologies related to neurological and metabolic treatments, including developments associated with Alzheimer’s disease and diabetes. He has also worked on intellectual property matters involving bisphosphonates and other pharmaceutical compounds.
Dr. Meier’s work further covers fermentation technologies and microbiology, including amino acid production, alcohol fermentation, and brewing processes. Additional areas include stem cell technologies, RNA-related developments such as miRNA and siRNA diagnostics and therapeutics, SNP diagnostics, biomarkers, and microbiological testing methods. His practice has also involved diagnostic technologies for pathogens including M. tuberculosis, anthrax, HPV, HCV, and HIV, as well as personalized medicine approaches, companion diagnostics, dosage and treatment regimens, transgenic technologies, and research tools. He has also handled intellectual property matters relating to sequencing technologies, gene modification techniques, and biophysical methods such as laser-based and thermophoresis technologies.
In addition to his client work, Dr. Meier advises companies and research organizations on employee invention matters, remuneration issues, and intellectual property portfolio management. He is active in professional organizations and currently serves as Chairman of the AIPPI Biotech Committee. Dr. Meier regularly presents and lectures on topics relating to patentability in biotechnology, biocomputing inventions, and procedural aspects of patent law. He has authored and co-authored publications on intellectual property matters, including the book “From Clones to Claims,” which examines the European Patent Office’s approach to biotechnology compared with U.S. and Japanese practice (6th edition, December 2015). He also teaches in the legal training course (D-course) at CEIPI of the Université de Strasbourg and has lectured at the University of Würzburg, Zeppelin University in Friedrichshafen, and the Management Center Innsbruck (MCI) in Austria.
